Sign in

Bill Dynan - NAR Cancer Editor

@nar-cancer-editor.bsky.social
298 followers 154 following 68 posts

Editor of fully Open Access journal publishing articles at the intersection of the nucleic acids research and cancer fields.

PostsRepliesMedia
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 27/09/2026
New tool in the breast cancer toolbox: eRNACare, a public web application for individualized survival and tumor probability scoring based on validated panels of enhancer RNAs. New in NAR Cancer. academic.oup.com/narcancer/ar...
academic.oup.com
Integrative multi-omics profiling and machine learning reveal enhancer RNA signatures for early detection and prognostic stratification in breast cancer
Abstract. Current breast cancer biomarkers rely predominantly on protein-coding transcriptomes, leaving the regulatory information encoded by enhancer RNAs
020
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 14/09/2026
First articles published in NAR Cancer 2026 Collection: Seeds of Cancer, Decades of Silence: Ageing and Environmental Control of Tumor Latency. Cancer risk can originate early in life, yet malignancy often emerges decades later. Let's explore that latency! 1/3
100
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 05/09/2026
Glioblastoma remains one of the most feared cancers. Here, in vivo-selected, shape-based DNA aptamers are used to replace the large antibodies used in conventional drug conjugates - unbiased approach to a problem that rational design has yet to overcome. academic.oup.com/narcancer/ar...
academic.oup.com
In vivo selection of anti-glioblastoma DNA aptamer-drug conjugates in an orthotopic patient-derived xenograft model
Abstract. Glioblastoma (GBM) is an aggressive, high-grade glioma with a near-universally fatal prognosis. Therapeutic failure is often attributed to the hi
020
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 29/08/2026
Ewing sarcoma tumor fitness depends on three snoRNA host genes–SNHG1, SNHG12, and SNHG30–that regulate chemical modification of ribosomal RNA. Blocking them slowed tumor growth, pointing to a strategy to target the unique EWS-FLI1 biology sustaining Ewing sarcoma. academic.oup.com/narcancer/ar...
academic.oup.com
SNHG family lncRNAs promote Ewing sarcoma cell fitness through intronic snoRNA-guided rRNA modifications
Abstract. Over 90% of Ewing sarcomas (EWS) are driven by the EWS–FLI1 fusion oncoprotein. EWS–FLI1 acts as a pioneer transcription factor, altering the exp
020
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 22/08/2026
The quest to identify genetic susceptibility to breast cancer continues - of 33 clinically identified RAD51C variants, several have intermediate homologous recombination deficiencies, and some have distinct therapeutic vulnerabilities. New in NAR Cancer: academic.oup.com/narcancer/ar...
academic.oup.com
RAD51C breast cancer-identified variants with attenuated homologous recombination function exhibit sensitivity to combined PARP1 and ATR inhibition
Abstract. The tumor suppressor RAD51C is essential for DNA double-strand break repair through the homologous recombination (HR) pathway. RAD51C loss is lin
071
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 18/06/2026
NAR Cancer 2025 impact factor rises to 4.6; other metrics at journal home page. Appreciate our authors, reviewers, editors. Encourage submissions at intersection of cancer and nucleic acids fields–full info and details of forthcoming "Seeds of Cancer" collection at academic.oup.com/narcancer/pa...
academic.oup.com
Call for Papers
NAR Cancer is a peer-edited, not-for-profit, Open Access journal published by Oxford University Press. In seven years, it has established a reputation for high-
031
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 07/06/2026
PARP inhibitors work in BRCA-mutant cancers, but resistance is common. Buckley-Benbow et al. show loss of CHTF18-RFC2/5 sensitizes cells via replicative gaps (not recombination defects), and isn’t rescued by 53BP1 loss—highlighting new therapeutic targets. academic.oup.com/narcancer/ar...
academic.oup.com
Loss of CHTF18–RFC2/5 leads to replicative gaps and sensitivity to PARP inhibitors
Abstract. The use of PARP inhibitors (PARPi) has profoundly changed the treatment of BRCA1/BRCA2-mutated cancers. Despite this, acquired resistance to PARP
000
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 27/05/2026
Can SMC5/6 status help guide precision cancer therapy? A new NAR Cancer study links deleterious SMC5/6 variants to tumor mutational burden and immunotherapy responses, driven via POLE dysfunction and mismatch repair deficiency.https://academic.oup.com/narcancer/article/8/2/zcag012/8688771
academic.oup.com
Disruption of the structural maintenance of chromosomes 5/6 complex enables tumor mutagenesis
Abstract. The structural maintenance of chromosomes (SMC) 5/6 complex is conserved and essential for mammalian development. SMC5/6 germline variants in cel
061
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 07/05/2026
Few cancer driver mutations have been identified in promoters, maybe for technical reasons. New assay targets >3,000 promoters — hits in CDK4, SMAD3, and GATA3 in breast cancer provide promising leads for functional follow-up. academic.oup.com/narcancer/ar... #CancerGenomics #NonCoding #Promoters
academic.oup.com
Sensitive detection of somatic mutations in GC-rich cancer gene promoters
Abstract. Somatic mutations in protein-coding genes and noncoding regulatory regions are the major drivers of cancer. Only a relatively small number of som
011
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 23/04/2026
Testicular germ cell cancer risk is rising, with disproportionate impact on Hispanic men. New NAR Cancer study of Mexican patients found 7 genes and 3 new genetic variants linked to risk. Inclusive research promotes fair, effective precision medicine. #HealthEquity academic.oup.com/narcancer/ar...
academic.oup.com
Uncovering novel germline variants associated with testicular germ cell tumors by exome sequencing
Abstract. Testicular germ cell tumors (TGCT) are highly heritable malignancies that display increasing incidence worldwide, with rising mortality rates par
000
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 13/04/2026
How does c-MYC overexpression drive transcriptional rewiring in cancer? Sundaram et al report a plausible mechanism involving co-option of TRE/AP1 sites, mainly at enhancers, rising with MYC levels and linked to repression. academic.oup.com/narcancer/ar...
academic.oup.com
MYC and AP-1 oncogenes cooperatively bind enhancers to rewire transcription
Abstract. The transcription factor c-MYC (MYC) is deregulated in ~70% of human cancers. Through de novo motif discovery analysis on published MYC ChIP-seq
031
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 15/03/2026
HSF1 drives cancer stress resilience but is hard to target—clever screen identifies spliceosome helicase DHX8 as a druggable regulator of HSF1 splicing→HSF1 program gone, cancer loses stress defenses. Editor's Choice in NAR Cancer. #PrecisionOncology #Spliceosome academic.oup.com/narcancer/ar...
academic.oup.com
Human DEAH-box helicase 8 regulates HSF1-mediated stress response and cancer-associated pre-mRNA splicing in tumour cells
Abstract. Transcription factor heat shock factor 1 (HSF1) orchestrates the cellular stress response, promoting malignant transformation, unchecked prolifer
021
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 27/02/2026
Introducing IGIS, a versatile, scalable platorm to investigate synthetic lethal relationships between cancer therapeutic targets. Haracska et al. describe the platform and validate it by investigation of BRCA1–RAD18 interplay. New in NAR Cancer. academic.oup.com/narcancer/ar...
academic.oup.com
Advancing inducible gene-inactivation systems to explore synthetic lethality
Abstract. Synthetic lethality offers opportunities to identify therapeutic targets for cancer research, facilitating the development of targeted tumour the
000
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 21/02/2026
Kavalipati, Aponte, et al. reveal actionable ways to overcome CDK4/6 resistance in HR+ breast cancer — a step toward smarter combination therapies and better patient outcomes. New in NAR Cancer: academic.oup.com/narcancer/ar...
academic.oup.com
Validate User
000
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 21/02/2026
NAR Cancer presents a curated collection of 17 articles on how advances in understanding the DNA damage response are reshaping cancer therapy. Explore the collection and read the editorial from guest editors Li Lan and Elise Fouquerel. New targets and new tools. academic.oup.com/narcancer/pa...
academic.oup.com
5th Anniversary Thematic Collection: Manipulating DNA Repair and the DNA Damage Response to Improve Cancer Therapy
This collection is coordinated with the journal’s virtual 5th Anniversary Symposium and is focused on exploitation of the DNA damage response for
084
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 18/02/2026
Terrific on-line seminar - Feb 19 noon EST. Kyungjae Myung, Recent NAR Cancer author, now Director of IBS Center at Ulsan National institute, Korea. "Investigation of genomic integrity & translation for potential clinical applications." Columbia Social DNAing: columbiacuimc.zoom.us/webinar/regi...
columbiacuimc.zoom.us
Welcome! You are invited to join a webinar: Social DNAing Webinar. After registering, you will receive a confirmation email about joining the webinar.
Welcome! You are invited to join a webinar: Social DNAing Webinar. After registering, you will receive a confirmation email about joining the webinar.
000
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 14/02/2026
New in NAR Cancer: PARP14 binds ssDNA via RRM domains and engages MRE11 at reversed forks, causing stress-induced DSBs—clarifying PARP14’s role in promoting chemosensitivity in BRCA-deficient cells. academic.oup.com/narcancer/ar...
academic.oup.com
The RRM domains of PARP14 mediate replication fork degradation in BRCA2-deficient cells
Abstract. Degradation of reversed replication forks by nucleases has emerged as a major mechanism of chemosensitivity in BRCA-deficient cells. We previousl
010
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 02/02/2026
Early oncogenic perturbations persist for decades, while overt tumorigenesis is constrained. How? CALL FOR PAPERS. NAR Cancer thematic collection. Gabriella Ficz (Queen Mary University London) and Yvonne Fondufe-Mittendorf (Van Andel Institute), eds. For details: academic.oup.com/narcancer/pa...
academic.oup.com
Seeds of Cancer, Decades of Silence: Ageing and Environmental Control of Tumour Latency
Editors: Gabriella Ficz, PhD Barts Cancer Institute (CRUK), Queen Mary University, London, UK g.ficz@qmul.ac.uk Yvonne Fondufe-Mittendorf, PhD Van Andel Inst
000
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 20/01/2026
Insights into how Rad 18 shapes oral cancer genomes by promoting error-free lesion bypass during DNA replication. Read more about how gene-environment interactions determine cancer risk in an NAR Cancer Article from Anand, Williams, Vaziri, and UNC coworkers. academic.oup.com/narcancer/ar...
academic.oup.com
Differential roles of Rad18 in repressing carcinogen- and oncogene-driven mutagenesis in vivo
Abstract. The DNA repair protein RAD18 activates “Y-family” trans-lesion synthesis (TLS) DNA polymerases that are DNA damage-tolerant and potentially error
010
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 08/12/2025
New in NAR Cancer: Colón-Rios, Glazer, and coworkers model PARPi resistance in the IDH1-mutant setting and offer a strategy to overcome resistance by treating with the receptor tyrosine kinase inhibitor, cediranib - mechanism involves suppression of re-activated HDR factors. doi.org/10.1093/narc...
doi.org
PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7
Abstract. Acquired resistance presents a major challenge for targeted therapies, with initially responsive tumors eventually reverting underlying vulnerabi
030
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 19/11/2025
Fantastic speaker lineup, co-organized by NAR Cancer Editorial Board member John Tainer. One of a select few conferences that NAR Journals will extend sponsorship to this year.
020
Reposted by Bill Dynan - NAR Cancer Editor
Liz Lyons @drlizlyons.bsky.social · 07/11/2025
James Watson, Co-Discoverer of the Structure of DNA, Is Dead at 97 www.nytimes.com/2025/11/07/s...
nytimes.com
James Watson, Co-Discoverer of the Structure of DNA, Is Dead at 97
01013
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 07/11/2025
Excited to share: NAR Cancer Editor's Choice review article from Kyungjae Myung and colleagues provides a snapshot of the blossoming field of DNA damage response- and repair-targeted therapeutics. Focus is on small molecules currently in clnical trials. academic.oup.com/narcancer/ar...
022
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 13/10/2025
Congratulations to Forment, O’Connor and coworkers on an Editors' Choice study in NAR Cancer, unraveling the mechanism by which addition of PARP inhibitors to AR pathway inhibitor therapy improves prostate cancer survival, even in the absence of HRR defects. academic.oup.com/narcancer/ar...
academic.oup.com
Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair
Abstract. Clinical trials show benefit of the combination of poly(ADP-ribose) polymerase inhibitors (PARPi) with androgen receptor (AR) pathway inhibitors
031
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 09/09/2025
New in NAR Cancer: Loss of uL14 downregulates antigen processing and presentation components in melanoma cell lines - alters peptide pool available for presentation to create an escape mechanism from immune surveillance. From Anna Dopler and coworkers.
020
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 08/09/2025
Evaluation of 49 mRNA modification regulators across subtypes in human breast cancer reveals potential biomarkers and therapeutic targets. New in NAR Cancer, from Carlos Paula, Erik Dassi, Francesca Aguilo and coworkers at University of Trento and Umeå University. academic.oup.com/narcancer/ar...
academic.oup.com
Analysis of the mRNA modification machinery alterations in breast cancer through the SCAN-B cohort
Abstract. Epitranscriptomic modifications regulate gene expression and have been implicated in cancer, including breast cancer. Using the SCAN-B cohort, we
010
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 19/08/2025
We described Ku-RNA binding in 1998, but had to wait 27 years for Zha and coworkers to discover the significance. A lesson in patience. 2/2 pubs.acs.org/doi/10.1021/...
pubs.acs.org
Characterization of the RNA Binding Properties of Ku Protein†
Ku protein, a heterodimer of 70 and 83 kDa polypeptides, is the regulatory component of the DNA-dependent protein kinase (DNA-PK). Ku protein binds to DNA ends and is essential for DNA double-strand b...
081
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 19/08/2025
Congrats to our Editorial Board member Shan Zha for amazing study attributing essentiality of Ku protein in primates to modulation of RNA-driven innate immunity. 1/2 www.nature.com/articles/s41...
nature.com
Ku limits RNA-induced innate immunity to allow Alu expansion in primates - Nature
Studies on the essentiality of Ku in human cells reveal that Ku interacts with diverse double-stranded RNA molecules, including antisense Alu, and enables tolerance of Alu sequence expansion in p...
031
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 15/08/2025
N6-methyladenosine in R-loop homeostasis. Short review in NAR Cancer from Chun-Long Chen and coworkers. Effects on transcription, repair, centromere and telomere stability, and R-loop dynamics. Targeting as a cancer therapeutic strategy. academic.oup.com/narcancer/ar...
academic.oup.com
m6A modification in R-loop homeostasis: a potential target for cancer therapeutics
Abstract. R-loops or DNA–RNA hybrids are prominent nucleic acid structures that commonly arise during transcription. These structures play important biolog
032
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 14/08/2025
Beyond BRCA status: machine-learning assisted multichannel imaging platform for cell-by-cell analysis of HR competency, enabling patient stratification. “Editor’s Choice” in NAR Cancer. academic.oup.com/narcancer/ar...
academic.oup.com
Automated machine learning profiling with MAP-HR for quantifying homologous recombination foci in patient samples
Abstract. Accurate visualization and quantification of homologous recombination (HR)-associated foci in readily available patient samples are critical for
043
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 10/08/2025
New insights into gene regulation in melanoma, the deadliest skin cancer: SETD6-catalyzed methylation of BRD4 and chromatin-localized interaction with MITF. From Tzofit Elbaz Biton, Dan Levy, and coworkers, published in NAR Cancer. academic.oup.com/narcancer/ar...
academic.oup.com
SETD6 mediates selective interaction and genomic occupancy of BRD4 and MITF in melanoma cells
Abstract. Aberrant transcriptional programs mediate malignant transformation of melanoma, the most aggressive form of skin cancer. The lysine methyltransfe
032
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 05/08/2025
Our sister journal, Nucleic Acids Research, has opened a search for an Executive Editor. Great opportunity for mid-career or senior investigator looking to be part of a great team, handle 100-150 papers per year, and attend the annual EE meeting. Details at: academic.oup.com/nar/pages/ex...
academic.oup.com
NAR seeks a new Executive Editor
Overview of the Journal Nucleic Acids Research (NAR) is a leading open access molecular biology journal published by Oxford University Press. It provides rapid
041
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 12/05/2025
Are key cancer driver mutations amenable to editing by endogenous ADAR enzymes? The scope of correctable mutations is charted for the first time in an Editor's Choice paper, newly published in NAR Cancer. From Rona Merdler-Rabinowicz and colleagues. academic.oup.com/narcancer/ar...
academic.oup.com
A systematic evaluation of the therapeutic potential of endogenous-ADAR editors in cancer prevention and treatment
Abstract. Adenosine deaminases acting on RNA (ADAR) enzymes constitute a natural cellular mechanism that induces A-to-I(G) editing, introducing genetic cha
110
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 26/04/2025
New in NAR Cancer. A critical examination of mutations in conserved m6A motifs: low recurrence and maybe not a primary mechanism for altering gene function. From Luis A. Diaz and coworkers, @mskcancercenter.bsky.social academic.oup.com/narcancer/ar...
000
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 18/04/2025
Watch the replay of Elise Fouquerel and Rob Sobol's talks at today's NAR Cancer 5th anniversary symposium (offered in collaboration with Social DNAing). Special thanks to guest host Li Lan. Link to video at the Social DNAing website: www.cancer.columbia.edu/research/pro...
cancer.columbia.edu
Social DNAing
Social DNAing Webinar Series, sponsored by the Cancer Genomics and Epigenomics Program at Columbia University, aims to provide a virtual meeting room for the genomic instability community worldwide.
010
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 15/04/2025
NAR Cancer 5th anniversary symposium on manipulating DNA repair and DDR for cancer therapy - 4th and final session, Thursday April 17, noon Eastern. Elise Fouquerel and Rob Sobol on emerging targets. Link to free registration: academic.oup.com/narcancer/pa...
Photos and titles for talks - Elise Fouquerel - PARP2 in the response to replication stress, Rob Sobol, BER enzymes and complexes as essential for PARP and PARG inhibitor response.
042
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 17/03/2025
Replay of two great talks from last week's NAR Cancer 5th anniversary symposium on manipulating the DNA damage response. Dale Ramsden on DNA polymerase theta - what it repairs and when, and Katie Pawelczak on a first-in-class RPA inhibitor. Find the link at www.cancer.columbia.edu/research/pro...
cancer.columbia.edu
Social DNAing
Social DNAing Webinar Series, sponsored by the Cancer Genomics and Epigenomics Program at Columbia University, aims to provide a virtual meeting room for the genomic instability community worldwide.
020
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 10/03/2025
NAR Cancer 5th Anniversary symposium in cooperation with Social DNAing: Thursday, March 13, noon US Eastern. Dale Ramsden on Pol theta and Katie Pawelczak on targeting RPA. Program info and link to register: academic.oup.com/narcancer/pa...
Headshot, affiliation, and title of symposium presentation. Dale Ramsden, Univ North Carolina, Polymerase theta - what damage is it repairing and when?;  Katie Pawelczak, NERx Biosciences, Targeting the DDR sensor RPA for first-in- class cancer therapy.
033
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 10/03/2025
Novel approach for simultaneous profiling of long-range genetic and epigenetic changes in matched cancer samples, focusing on clear cell renal cell carcinoma. New in NAR Cancer. From Sapir Margalit, Yuval Ebenstein, and others, Tel Aviv University. academic.oup.com/narcancer/ar...
academic.oup.com
Optical genome and epigenome mapping of clear cell renal cell carcinoma
Abstract. Cancer cells display complex genomic aberrations that include large-scale genetic rearrangements and epigenetic modulation that are not easily ca
000
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 05/03/2025
New Cancer Grand Challenges announced: mechanisms driving unassigned mutational signatures, the dark proteome, and more: www.cancergrandchallenges.org/new-challeng...
cancergrandchallenges.org
New challenges
Explore the challenges currently open for Expressions of Interest.
011
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 05/03/2025
Reaching out to #earlycareerinvestigators @narjournal.bsky.social
010
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 27/02/2025
First in vivo DNA aptamer selection using an orthotopic patient-derived xenograft glioblastoma mouse model to identify tumor-homing DNA aptamers. From Caroline Doherty, LJ Maher and colleagues at Mayo Clinic. New in NAR Cancer. academic.oup.com/narcancer/ar...
academic.oup.com
In vivo selection of anti-glioblastoma DNA aptamers in an orthotopic patient-derived xenograft model
Abstract. Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor of adults. Current therapeutic options yield dismal prognoses
040
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 22/02/2025
New in NAR Cancer - Use of human artificial chromosome (HAC)-based assay to analyze chromosomal instability in IDH-mutant gliomas suggests a precision medicine approach to improve therapeutic outcomes - from Goncharov and coworkers. academic.oup.com/narcancer/ar...
academic.oup.com
Therapy enhancing chromosome instability may be advantageous for IDH1R132H/WT gliomas
Abstract. Recently revised brain tumor classification suggested a glioma treatment strategy that takes into consideration molecular variants in IDH1 and TP
031
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 14/02/2025
In NAR Cancer: Loss of powerful G4 resolvase FANCJ sensitizes to G4-stabilizing ligand - shown in cancer cells and in C. elegans in vivo. Proof-of-principle for synthetic lethality-based therapeutic approach. Marcello Germoglio et al, IBBC and University of Naples. academic.oup.com/narcancer/ar...
Fluorescence micrograph of C. elegans dog-1-deficient worm labeled for G4 foci
030
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 14/02/2025
Watch the replay - terrific and well attended talks from Kara Bernstein (RAD51 paralogs) and Joanna Loizou (pol theta) yesterday at the NAR Cancer 5th anniversary symposium. Link to "watch the latest replay" at www.cancer.columbia.edu/research/pro...
Title slides and headshots for Kara Bernstein and Joanna Loizou
083
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 14/02/2025
This is terrific to see! Proud graduate student Dory Fawwal presents her new NAR Cancer paper to her peers and colleagues. Oncohistone H3E50K. academic.oup.com/narcancer/ar...
010
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 11/02/2025
NAR Cancer 5th anniversary symposium on manipulating DNA repair and the DDR - Session 2 this Thursday, Feb 13, noon US Eastern time. Kara Bernstein and Joanna Loizou speaking. In collaboration with Social DNAing. Information and free registration link at academic.oup.com/narcancer/pa...
Symposium speakers and title
02210
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 07/02/2025
NAR Cancer 5th anniversary symposium with Social DNAing - Manipulating DNA repair for cancer therapy. 2nd session Feb. 13. Kara Bernstein (Penn) on insights from HR variants and Joann Loizou (ICR) on Pol theta gap processing and fork progression. Register at: columbiacuimc.zoom.us/webinar/regi...
columbiacuimc.zoom.us
Welcome! You are invited to join a webinar: Social DNAing Webinar. After registering, you will receive a confirmation email about joining the webinar.
Welcome! You are invited to join a webinar: Social DNAing Webinar. After registering, you will receive a confirmation email about joining the webinar.
030
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 06/02/2025
New in NAR Cancer: Oncogenic histone variant H3E50K changes chromatin accessibility, dysregulates gene expression, and supports an EMT phenotype. From Kirti Sad, Anita Corbett, Jennifer Spangle and colleagues at Emory University Winship Cancer Institute. academic.oup.com/narcancer/ar...
bsky.app
020
Bill Dynan - NAR Cancer Editor @nar-cancer-editor.bsky.social · 04/02/2025
Encourage reading Keith Caldecott's obituary for Larry Thompson, published in the February issue of DNA repair - "A life of bikes, birds, and DNA repair (1941-2024). doi.org/10.1016/j.dn...
doi.org
Redirecting
041